Market evolution: Insulin (CN 293712) — 2015–2025

Introduction

Insulin (CN 293712) is a critical biopharmaceutical product used primarily as a hormone in the treatment of diabetes, one of the world's most prevalent chronic conditions. As both a public-health essential and a high-value industrial output, insulin trade flows carry significant implications for strategic autonomy, industrial competitiveness, and health security. This report examines the evolution of EU extra-Union trade in insulin and its salts over the period 2015–2025, drawing on annual customs and production data.

Over this decade, the EU's position in the global insulin market underwent a dramatic transformation. The Union shifted from being a significant net importer—relying on external suppliers for nearly 64% of apparent consumption—to becoming a net exporter by 2025. This reversal was underpinned by an extraordinary expansion of EU domestic production and a concurrent collapse in import volumes and values, particularly from the United States. At the same time, export flows contracted in absolute terms but gained weight relative to the enlarged production base, and the market experienced several notable price and supply shocks.

The following analysis is structured around three principal dynamics: the trade balance reversal and production surge, the realignment of trade partnerships, and the market's exposure to price compression, volatility, and concentration risks.

1. The Great Reversal: From Net Import Dependence to Export Surplus

The EU's insulin trade balance completed a structural inversion over the decade

In 2015, the EU ran a trade deficit of €104.4 million in insulin, importing €746.9 million while exporting €642.5 million. By 2025, this had transformed into a surplus of €75.3 million: imports had collapsed to €72.0 million while exports, though also declining, remained at €147.3 million.

The net import reliance indicator crystallises this shift: the EU moved from depending on external suppliers for nearly two-thirds of its apparent consumption to exporting substantially more than it imports. Over the full period, the trade deficit reached a minimum of −€907.3 million at its worst point, before reversing completely.

Domestic production expanded at an extraordinary pace

Behind the trade balance reversal lies a remarkable expansion of EU domestic production. According to Prodcom data (code 21.10.52.00), EU production of insulin grew from a value of approximately €1.09 billion in 2015 to €24.0 billion in 2025—an increase of 2,102.4%. Measured in gross tonnage (GT), the supplementary unit used for this product, production surged from approximately 619 million GT to 40.0 billion GT (+6,364.9%).

This extraordinary growth reflects the EU's dominant position in global insulin manufacturing, anchored by multinational producers such as Novo Nordisk (Denmark) and Sanofi (France), which have invested heavily in capacity expansion to meet surging global demand driven by the diabetes epidemic. It should be noted that gross tonnage is a shipping-related volumetric measure rather than a pharmaceutical mass metric; the divergence between the quantity increase (+6,364.9%) and the value increase (+2,102.4%) suggests a decline in value per GT, potentially reflecting shifts in product mix toward higher-volume finished formulations and delivery devices.

Export propensity strengthened even as absolute trade values declined

While both import and export values fell in absolute terms, the export propensity—the ratio of exports to domestic production—rose from 60.1% in 2015 to 73.3% in 2025 (+22.1%). This indicates that an increasing share of the EU's vastly expanded production base is directed toward external markets.

At the same time, trade intensity (total trade as a share of production) declined from 88.3% to 81.9% (−7.2%). The combination of rising export propensity and falling trade intensity is consistent with imports declining faster than the growth of the domestic market, while a growing share of enlarged production is exported.

2. The Reshaping of Global Partnerships: US Dominance Erodes, New Corridors Emerge

The United States' near-monopoly on EU insulin imports contracted sharply

In 2015, the United States supplied 99.7% of EU insulin imports by value (€744.4 million out of €746.9 million). By 2025, US-origin imports had fallen to €70.9 million—a decline of 90.5%. While the United States remained the dominant import source by far, its absolute dominance eroded substantially as the overall import market shrank.

The import concentration HHI by value remained extremely elevated throughout the period (from 9,933 to 9,828 on a 0–10,000 scale), confirming the persistently oligopolistic structure of EU insulin imports. This near-monopoly concentration reflects both the dominance of US pharmaceutical companies in the branded insulin market and the high barriers to entry in biologic drug manufacturing.

Small but emerging import sources signal evolving supply diversification

While the United States dominated, several smaller suppliers gained ground from very low bases. India's exports to the EU grew from a negligible €403 to €138,024 (+34,191%), reflecting India's expanding role as a global insulin active pharmaceutical ingredient (API) manufacturer. The United Kingdom's exports to the EU rose from €14,394 to €156,492 (+987.2%), possibly reflecting post-Brexit trade recalibration.

China, conversely, saw its exports to the EU collapse from €2.5 million to just €1,466 (−99.9%), effectively exiting the market. The United Arab Emirates also saw a decline, from €295,102 to €178,336 (−39.6%). These shifts, though small in absolute terms relative to the US dominance, suggest a gradual diversification of the EU's import base.

Denmark anchors EU insulin exports, though volumes and values have contracted significantly

Denmark accounted for the vast majority of EU insulin exports, with €599.0 million in 2015 declining to €133.4 million in 2025 (−77.7%). This reflects the export activities of Novo Nordisk, the world's largest insulin producer, headquartered in Denmark.

Germany's exports proved relatively resilient (−14.4%), while France experienced a sharper contraction (−87.9%). Notably, Poland (+15.1%), Belgium (+480.9%), and Austria (+2,717.7%) bucked the downward trend, though from smaller bases. Poland's steady growth to €3.4 million made it the only major EU exporter to increase its absolute export value over the decade.

Confidential destination reporting dominates EU export statistics

A striking feature of EU insulin export destinations is that the dominant partner category is "Countries and territories not specified for commercial or military reasons," which accounted for €599.0 million in 2015 and €133.4 million in 2025. This category closely mirrors Denmark's export figures, suggesting that the bulk of Danish insulin exports are reported under confidential destination codes—likely reflecting the commercial sensitivity of pharmaceutical trade data.

Among disclosed destinations, the United States remained the largest at €15.6 million (2015), declining to €7.9 million (2025, −49.5%). India emerged as a growing destination (€78,605 → €428,489, +445.1%), while Vietnam collapsed from €697,914 to €5,684 (−99.2%). South Korea (+504.3%) and the Democratic Republic of Congo (+167.7%) also registered notable growth from small bases.

3. Price Compression, Volatility, and Structural Concentration Risks

Trade unit values fell steeply across both imports and exports

The price per tonne of traded insulin declined sharply over the period. Import unit values dropped most dramatically, falling from €163.2 million per tonne to €21.5 million per tonne (−86.8%), while export unit values fell from €23.0 million per tonne to €9.1 million per tonne (−60.2%).

The much higher import unit values in 2015 are consistent with the EU importing primarily high-value finished insulin products (e.g., patented analogues and pre-filled pens) from US pharmaceutical companies. The dramatic convergence of import and export prices by 2025 suggests a structural shift in trade composition—potentially toward more API or biosimilar-type products—or reflects broader global insulin price competition driven by biosimilar market entry and policy pressure on drug pricing.

The market experienced several notable price and supply shocks

The volatility analysis identified three significant shock events in EU insulin trade:

The most significant shock was a price spike in EU exports to India in 2022, with an abnormality score of 610.1 and a year-on-year shift of over 6,000%. This extreme price movement likely reflects India's surging demand amid its diabetes epidemic combined with constrained supply of specialised insulin products. The UK import price shock of 2019 (+1,086.7%), while statistically prominent, affected a negligible share of total import value and is likely an artefact of small-volume transactions at extreme unit values. The Vietnam supply shock of 2018 (−99.8%) indicates a near-complete cessation of EU exports to that market, possibly due to Vietnam developing domestic production capacity or redirecting procurement toward alternative suppliers such as China or India.

Across all partner relationships, import volatility was generally lower for the dominant US supplier (coefficient of variation of 0.35) than for smaller partners such as the United Kingdom (1.66), India (1.43), or Switzerland (1.47). On the export side, China exhibited the highest volatility (CV of 2.14), followed by the Russian Federation (1.33) and India (1.04).

Import concentration remains extreme, while export concentration is moderate and rising

The import concentration HHI by value remained at near-monopoly levels throughout the decade, declining only marginally from 9,933 to 9,828 (−1.1%). However, by volume the HHI fell significantly from 9,243 to 5,031 (−45.6%), suggesting that while the US continues to dominate high-value imports, smaller suppliers are gaining meaningful volume shares.

Export concentration by value increased moderately (3,863 → 4,192, +8.5%), suggesting a consolidation around fewer export destinations, likely driven by the dominance of confidential-category flows. By volume, however, export concentration decreased (3,577 → 2,910, −18.6%), pointing to some diversification in lower-value export flows toward emerging markets.

Specialisation is unevenly distributed across EU member states

The specialisation analysis for 2025 reveals pronounced disparities across EU member states in revealed comparative advantage (RCA) and the normalised RSCA index:

Portugal exhibits an exceptionally high RCA of 49.37, though its overall market share remains small (0.68% of production, 1.4% of total trade). France, home to Sanofi, holds a genuine comparative advantage (RCA 2.82, RSCA 0.48) with a substantial production share of 22.0%. Germany, despite accounting for 21.2% of total EU insulin trade, has an RCA well below 1 (0.33), indicating that insulin is not a specialised output relative to its broader chemical and pharmaceutical sector. This suggests Germany's role is more that of a large trading hub than a specialised insulin producer.

Conclusion

The EU insulin market (CN 293712) underwent a profound structural transformation between 2015 and 2025. What began the decade as a market dependent on imports—predominantly from the United States—ended it as one where the EU is a net exporter backed by vastly expanded domestic production capacity.

Three principal conclusions emerge from this analysis:

1. Strategic autonomy has markedly strengthened. The EU's net import reliance shifted from +64.3% to −34.9%, driven by an extraordinary expansion in domestic production (from €1.09 billion to €24.0 billion in value). The Union has established itself as a global leader in insulin manufacturing, substantially reducing its vulnerability to external supply disruptions in this critical pharmaceutical product.

2. Trade partnerships are being fundamentally reshaped. The United States' share of EU imports collapsed by 90.5% in absolute terms, though it remained the overwhelmingly dominant supplier with an import HHI near 10,000. Export flows are anchored by Denmark and directed largely toward confidential-destination categories, reflecting the strategic and commercial sensitivity of insulin trade. Emerging suppliers such as India are gaining ground from low bases, while China has effectively exited the EU import market.

3. The market faces structural pressures alongside its strengthened position. Falling unit values—import prices down 86.8%, export prices down 60.2%—suggest intensifying global price competition, potentially driven by biosimilar entry and policy reforms on insulin pricing. While import concentration remains extremely high by value, meaningful diversification is occurring by volume. The detection of significant price and supply shocks—including the 2022 India export price spike and the 2018 Vietnam supply cessation—underscores the need for continued monitoring of trade volatility.

Overall, the EU's insulin trade trajectory over this decade reflects a successful industrial strategy anchored by a small number of dominant producers, which has fundamentally altered the Union's position from that of a dependent importer to a globally significant exporter of this life-essential medicine.